Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Adults

1 Apr 2022

Abstract excerpt

Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) is the most common subtype of B-ALL in adults and its incidence increases with age. It is characterized by the presence of BCR-ABL oncoprotein that plays a central role in the leukemogenesis of Ph+ ALL. Ph+ ALL patients traditionally had dismal prognosis and long-term survivors were only observed among patients who underwent allogeneic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to CAR-T cell therapy research
Share to Chronic Myeloid Leukemia Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35406576
DOI: 10.3390/cancers14071805

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in AdultsPMID 35406576Read ↗

Ph+ ALL: new approaches for upfront therapySemantic proximity Read ↗

How has the management of Ph+ acute lymphoblastic leukemia (ALL) changed over the years.Semantic proximity Read ↗

Treatment and outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults after relapse.Semantic proximity Read ↗

Evidence-Based Minireview: What is the optimal tyrosine kinase inhibitor for adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia?Semantic proximity Read ↗

Role of Allogeneic Hematopoietic Stem Cell Transplantation for Philadelphia Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia in the Contemporary EraSemantic proximity Read ↗

Management of adult Ph-positive acute lymphoblastic leukemia.Semantic proximity Read ↗

Integrative Insights into Philadelphia-like B-Cell Acute Lymphoblastic Leukemia: A Genetic and Molecular LandscapeSemantic proximity Read ↗

How I treat Philadelphia chromosome–like acute lymphoblastic leukemia in children, adolescents, and young adultsSemantic proximity Read ↗

The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia or Philadelphia chromosome‐like acute lymphoblastic leukemiaSemantic proximity Read ↗

Philadelphia Chromosome–Positive Acute Lymphocytic Leukemia: A New Era of ChallengesSemantic proximity Read ↗

Treatment of Philadelphia Chromosome–Positive Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.